We are live on ! Find out more
KA

Kinnevik AB Portfolio holdings

AUM $65.6M
1-Year Est. Return 25.95%
This Fund
S&P 500
This Quarter Est. Return
-24.77%
1 Year Est. Return
-25.95%
3 Year Est. Return
-51.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$89.3M
AUM Growth
-$14.5M
Cap. Flow
+$13.1M
Cap. Flow %
14.65%
Top 10 Hldgs %
100%
Holding
1
New
–
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
RXRX icon
Recursion Pharmaceuticals
RXRX
+$13.1M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXRX icon
1
Recursion Pharmaceuticals
RXRX
$1.58B
$89.3M 100%
11,905,668
+1,500,000
+14% +$13.1M

Similar funds

TCP
Teleios Capital Partners Zug $65.7M AUM 48.76% 1-Year Est. Return
MMC
Mainsail Management Company Austin, Texas $66M AUM 18.6% 1-Year Est. Return
MIG
Mithril II GP Austin, Texas $64.5M AUM 360.75% 1-Year Est. Return
KAM
Kinney Asset Management Chicago, Illinois $67.1M AUM 29.09% 1-Year Est. Return
MA
MAS Advisors Miami, Florida $63.2M AUM 9.63% 1-Year Est. Return
EVP
Evergreen Venture Partners Tel Aviv, Israel $68.4M AUM 1.49% 1-Year Est. Return
TIM
Tikehau Investment Management Paris, France $68.4M AUM 23.35% 1-Year Est. Return
A
Atomvest Hong Kong $68.5M AUM 4.6% 1-Year Est. Return

Kinnevik AB's Q2 2024 Portfolio in Review

As of Q2 2024, Kinnevik AB held 1 position worth $89.3M, down 14% from $104M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Kinnevik AB deployed $13.1M of net new capital in Q2 2024, adding to 1 existing holding.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Kinnevik AB added most to Recursion Pharmaceuticals in Q2 2024, an estimated $13.1M increase.
  • Kinnevik AB's ten largest holdings make up 100% of its $89.3M portfolio in Q2 2024.
  • Kinnevik AB opened 0 new positions and closed 0 in Q2 2024.
  • Kinnevik AB's portfolio value fell 14% quarter-over-quarter to $89.3M.

Based on Kinnevik AB's 13F filing for Q2 2024, filed 8 Jul 2024.